Markey joined a coalition of 76 cancer centers and national organizations to encourage Americans to stay on track with cancer screenings and treatment during the pandemic.
LEXINGTON, Ky. (Jan. 29, 2021) The University of Kentucky Markey Cancer Center is teaming up with the National Comprehensive Cancer Network® (NCCN®), the American Cancer Society (ACS) and other leading cancer organizations across the country to endorse the resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
The coalition of 76 organizations has released an open letter reminding the public that cancer still poses a major threat to people’s health, but acting as soon as is safely possible can lead to much better outcomes in the future. The letter examines distressing trends showing a significant drop-off in recommended cancer screening and treatment compared to prior years. This concerning side-effect of the pandemic could lead to a staggering number of preventable cancer death
of
LEXINGTON, Ky. (Jan. 28, 2021) UK HealthCare, home to the University of Kentucky Markey Cancer Center, has officially been recognized as a System of Excellence for Hidden Scar breast cancer surgery, the highest level of Hidden Scar designation. UK HealthCare is the first and only hospital system in Kentucky to be certified as a Hidden Scar System of Excellence. This surgical option provides the women of Kentucky with a procedure that effectively treats breast cancer while optimizing cosmetic results.
The American Cancer Society estimates that 3,800 Kentucky women will be diagnosed with breast cancer this year. Of those women, most will need surgery as part of their treatment. Though surgical techniques over the decades have improved, traditional breast cancer surgeries still leave visible scars behind.
Mindy Rogers has been named director of the Kentucky Cancer Program - East, housed within the UK Markey Cancer Center.
LEXINGTON, Ky. (Jan. 20, 2021) – The University of Kentucky Markey Cancer Center announces the appointment of Mindy Rogers as director of the Kentucky Cancer Program – East, which is housed within the Cancer Center.
The Kentucky Cancer Program (KCP) - East is one of the programs under Markey’s Community Impact Office. The KCP-East director works under the guidance of Markey’s Associate Director for Population Science and Community Impact Pamela Hull, Ph.D. In this role, Rogers will manage a staff of KCP-East Regional cancer control specialists whose efforts cover nine area development districts in the eastern half of the state.
A new study by Markey researchers shows a higher-than-average rate of DACH1 mutations in Kentucky patients with endometrial cancer.
LEXINGTON, Ky. (Jan. 12, 2020) A new study by University of Kentucky Markey Cancer Center researchers shows that DACH1 mutations are prevalent in Kentucky patients with endometrial cancer, suggesting that DACH1 may be a candidate biomarker for future trials with immunotherapy.
DACH1 is a transcriptional repressor and tumor suppressor gene that is frequently mutated in other cancers, including melanoma, bladder and prostate cancer. The loss of DACH1 expression is also associated with poor prognosis and reduced survival in women with uterine cancer.
Published in PLOS One, the study sought to determine the frequency of DACH1 mutations in patients with endometrial cancer in Kentucky. Using the Oncology Research Information Exchange Network (ORIEN), a personalized medicine consortium that Markey joined in 2017, researchers examined clinical and genomic
The mystery of India s missing clinical trial results bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.